Eli Lilly will invest more than $6 billion in a new manufacturing plant in Huntsville, according to online reports. The project represents the largest capital investment for a single development in Alabama’s history.
Major Manufacturing Expansion in Huntsville
The company plans to produce small-molecule synthetic and peptide medicines at the site, including the GLP-1 weight-loss pill orforglipron. Eli Lilly expects to hire 450 employees, including engineers, scientists, operations staff, and lab technicians.
In addition, online reports note that the plant will support a broad range of advanced manufacturing activity.
Construction Timeline and Economic Impact
Construction will begin in 2026 and finish in 2032. During that time, the project will create about 3,000 construction jobs, which will further boost the local economy.
Huntsville’s Greenbrier South location rose to the top of 300 competing sites because it offers strong utility access, transportation options, and favorable zoning. Its close proximity to the HudsonAlpha Institute for Biotechnology also strengthened the city’s case.
Local and State Response
Eli Lilly leaders praised Huntsville’s record of innovation and its skilled workforce. CEO David A. Ricks said the city offers an ideal environment to expand manufacturing for next-generation medicines.
Meanwhile, Gov. Kay Ivey celebrated the project and highlighted its economic impact. According to online reports, state officials view the investment as a major win for Alabama and the region.
Sign up for the Homely Huntsville newsletter to stay up to date on Huntsville.
